Osteoarthritis and Bone Disorders News

Novel therapies are providing hope in osteoporosis, but questions surrounding optimal treatment regimens remain, according to a presenter at the 2020 Congress of Clinical Rheumatology-East.

An extract made from Curcuma longa, commonly known as turmeric, outperformed placebo for the treatment of osteoarthritis-related knee pain in older adults but had no significant impact on knee effusion-synovitis or cartilage composition, data showed.

A number of compounds and therapeutic approaches moving through the pipeline may soon enrich treatment paradigms for osteoarthritis, according to a presenter at the 2020 Congress of Clinical Rheumatology-East.

Interleukin-1 inhibition with canakinumab may substantially reduce rates of total hip and knee replacement, as well as osteoarthritis symptoms, according to data published in the Annals of Internal Medicine.

When presented with a range of treatment options, patients with osteoarthritis reported that the most important outcomes are disease progression and improving pain and walking, noted researchers in Seminars in Arthritis and Rheumatism.

Nature abhors a vacuum, and in the absence of evidence-based therapies to treat or prevent COVID-19, stem cell clinics with a menu of unsubstantiated direct-to-consumer therapies are more than willing to fill the gap.

Occupations with heavy physical labor, such as cleaning, agricultural, service, house and construction work, as well as mining, are associated with greater odds of developing knee osteoarthritis, according to data published in Arthritis Care and Research.

Delaying denosumab doses by more than 4 months is associated with increased risks for vertebral fracture compared with on-time injections, according to findings published in Annals of Internal Medicine.

Treatment with vitamin D and omega-3 fatty acids supplements for a mean duration of 5.3 years failed to reduce chronic knee pain or improve function or stiffness, according to data published in Arthritis & Rheumatology.

Ticagrelor was associated with a 29% lower risk for osteoarthritis compared with another antiplatelet agent, clopidogrel, during a 5-year follow-up period, according to data published in Arthritis & Rheumatology.